2022 / 03

Next Paper
DOI: 10.24075/brsmu.2022.027

ORIGINAL RESEARCH

Assessment of ocular manifestation frequency and quality of life in chronic myeloproliferative disorders

Yunusova EM, Mukhamadeev TR, Bakirov BA
About authors

Bashkir State Medical University, Ufa, Russia

Correspondence should be addressed: Elvira M. Yunusova
Lenina, 3, 450008, Ufa, Russia; ur.liam@61anilluniaz

About paper

Author contribution: Yunusova EM — data collection and analysis, writing of the manuscript; Mukhamadeev TR — consulting, scientific editing of the manuscript; Bakirov BA — study concept and design, consulting.

Compliance with ethical standards: the study was approved by the Ethical Review Board at the Bashkir State Medical University (Protocol № 10 of 25 November 2020); all patients provided written informed consent for participation in the study.

Received: 2022-05-02 Accepted: 2022-05-17 Published online: 2022-05-29
|
  1. Lacerda JF, Oliveira SN, Ferro JM. Chronic myeloproliferative diseases. Chronic myeloproliferative diseases. Handb Clin Neurol. 2014; 120: 1073–81. DOI: 10.1016/B978-0-7020-4087-0.00072-3.
  2. Rumyanceva YuV, Karachunskij AI. Optimizaciya terapii ostrogo limfoblastnogo lejkoza u detej v Rossii i Belorussii. Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2007; 6 (4): 13. Russian.
  3. Breccia M, Gentilini F, Cannella L, Latagliata R, Carmosino I, Frustaci A, Alimena G. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res. 2008; 32 (7): 1022–5. DOI: 10.1016/j.leukres. 2007.10.016.
  4. Wahab A, Rafae A, Mushtaq K, asood A, Ehsan H, Khakwani M, Khan A. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma. Front Oncol. 2021; 11: 678634. DOI: 10.3389/ fonc.2021.678634.
  5. Rudneva LF, Ponomareva MN. Strategiya lecheniya glaz pri gemoblastozax. Medicinskaya nauka i obrazovanie Urala. 2019; 20 (2): 205–8. Russian.
  6. Chistyakova NV, Shadrichev FE, Kuznecova TI. Sluchaj izolirovannogo vnutriglaznogo recidiva ostrogo limfoblastnogo lejkoza. Oftal'mologicheskie vedomosti. 2017; 10 (3): 74–84. Russian.
  7. Dhasmana R, Prakash A, Gupta N, Verma SK. Ocular manifestations in leukemia and myeloproliferative disorders and their association with hematological parameters. Ann Afr Med. 2016; 15 (3): 97–103. DOI: 10.4103/1596-3519.188887.
  8. Soman S, Kasturi N, Srinivasan R, Vinod KV. Ocular Manifestations in Leukemias and Their Correlation with Hematologic Parameters at a Tertiary Care Setting in South India. Ophthalmol. Retina. 2018; 2 (1): 17–23. DOI: 10.1016/j.oret.2017.05.009.
  9. Grishina EE, Mamontov AO. Oftal'mologicheskie proyavleniya lejkoza. Al'manax klinicheskoj mediciny. 2016; 44 (5): 587–91. Russian.
  10. Sharma PV, Ilyas O, Jobanputra Y, Casanova T, Kalidindi V, Santos N. Is it always cancer? A curious case of benign intracranial hypertension in chronic myeloid leukemia. Intractable Rare Dis. Res. 2018; 7 (3): 182–4. DOI: 10.5582/irdr.2018.01045.
  11. Chinta S, Rani PK, Manusani U. Bilateral exudative retinal detachment as a presenting sign of acute lymphoblastic leukemia. Middle East Afr J. 2012; 19 (4): 410–2. DOI: 10.4103/09749233.102762.
  12. Rudneva LF, Vasilkova TN, Petrov IM., Ponomareva MN. Gemoblastozy. Osobennosti porazheniya glaz. Tyumen': Konovalov IS, 2020; 90 s. Russian.
  13. Mohamed SF, Qatami A, Nashwan A, Abdulla MA, Yassin MA. Ophthalmologic Manifestations as Initial Presentation of Patients with Chronic Myeloid Leukemia: Report of Two Cases. Case Rep Oncol. 2020; 13 (1): 7–11. DOI: 10.1159/000504928.
  14. Igonina IA. Osnovnye metody ocenki kachestva zhizni oftal'mologicheskix bol'nyx. Smolenskij medicinskij al'manax. 2017; 1: 152–6. Russian.
  15. Gabdrakhmanova AF, Kurbanov SA. Kliniko-funkcional'noe znachenie pokazatelej kachestva zhizni pri pervichnoj otkrytougol'noj glaukome. Nacional'nyj zhurnal glaukoma. 2015; 14 (4): 29–35. Russian.